Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Robert W. Schrier, Raymond.

Slides:

Advertisements

Similar presentations

Volume 69, Issue 5, Pages (March 2006)

Advertisements

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease American Journal of Kidney Diseases

Plasma sodium and hypertension

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Robert W. Schrier, Kimberly K. McFann, Ann M. Johnson

Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function Susan E. Shoaf, Patricia Bricmont, Suresh.

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Volume 88, Issue 2, Pages (August 2015)

‘Progressive diabetic nephropathy. How useful is microalbuminuria

Volume 83, Issue 2, Pages (February 2013)

Volume 81, Issue 7, Pages (April 2012)

Higher systolic blood pressure is associated with progression of carotid intima–media thickness in patients with chronic kidney disease Jessica Kendrick,

Need for better diabetes treatment for improved renal outcome

Nuhad Ismail, Bryan Becker, Piotr Strzelczyk, Eberhard Ritz

Volume 61, Issue 3, Pages (March 2002)

Volume 63, Issue 4, Pages (April 2003)

Volume 66, Issue 3, Pages (September 2004)

Progression of diabetic nephropathy

Volume 54, Issue 4, Pages (October 1998)

Volume 74, Issue 3, Pages (August 2008)

Renal risk scores: Progress and prospects

The epidemiology of chronic kidney disease

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Study of Heart and Renal Protection (SHARP)

Volume 61, Issue 4, Pages (April 2002)

Volume 57, Issue 2, Pages (October 2000)

Volume 74, Issue 9, Pages (November 2008)

Volume 62, Issue 4, Pages (October 2002)

Blood pressure targets in hemodialysis patients

Volume 81, Issue 5, Pages (March 2012)

Volume 68, Issue 2, Pages (August 2005)

Volume 66, Issue 2, Pages (August 2004)

Volume 82, Issue 7, Pages (October 2012)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Issue 4, Pages (April 2005)

Counteracting progression of renal disease: A look into the future

Volume 78, Issue 5, Pages (September 2010)

Volume 58, Issue 3, Pages (September 2000)

Volume 60, Issue 1, Pages (July 2001)

Volume 80, Issue 3, Pages (August 2011)

Volume 62, Pages S47-S52 (December 2002)

Volume 66, Pages S18-S21 (November 2004)

Volume 63, Issue 2, Pages (February 2003)

Volume 79, Issue 5, Pages (March 2011)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

The course of the remnant kidney model in mice

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Chirag R. Parikh, Peter Mcsweeney,

Volume 80, Issue 10, Pages (November 2011)

Volume 74, Issue 9, Pages (November 2008)

Volume 60, Issue 3, Pages (September 2001)

Robert G. Nelson, Hal Morgenstern, Peter H. Bennett

Volume 77, Issue 1, Pages (January 2010)

Michael R. Lattanzio, Matthew R. Weir Kidney International

Is it the low-protein diet or simply the salt restriction?

Volume 75, Issue 1, Pages (January 2009)

Clinical and cellular markers of diabetic nephropathy

Volume 63, Pages S13-S16 (February 2003)

Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa

Volume 68, Issue 3, Pages (September 2005)

Volume 87, Issue 3, Pages (March 2015)

Volume 64, Issue 4, Pages (October 2003)

Volume 58, Issue 2, Pages (August 2000)

Friends, social networks, and progressive chronic kidney disease

Volume 77, Issue 12, Pages (June 2010)

Volume 73, Issue 11, Pages (June 2008)

Volume 57, Pages S44-S48 (April 2000)

Presentation transcript:

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Robert W. Schrier, Raymond O. Estacio, Anne Esler, Philip Mehler Kidney International Volume 61, Issue 3, Pages 1086-1097 (March 2002) DOI: 10.1046/j.1523-1755.2002.00213.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Design and patient follow up rates for the ABCD Trial. Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Mean systolic(A) and diastolic (B) blood pressures ± standard errors according to intensive (solid line) versus moderate (dashed line) therapy throughout 5 years. T tests at each time interval revealed a significant and persistent blood pressure separation occurred after 6 months between the two interventions, P < 0.0001. Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Mean total cholesterol (normal range 130 to 200 mg/dL) and glycosylated hemoglobin (normal range 4.2 to 7.0%) values ± standard errors over 5-years for the intensive (solid line) versus moderate (dashed line) therapy (A), and nisoldipine (solid line) versus enalapril (dashed line) therapy(B). T tests at each time interval reveal no significant difference between the therapies. Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Mean creatinine clearances ± standard errors according to (A) intensive (solid line) versus moderate (dashed line) blood pressure control and (B) nisoldipine (solid line) versus enalapril (dashed line). Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Mean creatinine clearances ± standard errors according to intensive (solid line) versus moderate (dashed line) therapy for patients with normoalbuminuria (A) and microalbuminuria (B) at baseline. Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 6 Log urinary albumin excretion (UAE) for intensive (solid line) and moderate (dashed line) blood pressure control groups: (A) normoalbuminuria at baseline; (B) microalbuminuria at baseline. *T test performed at various time intervals revealed a P value <0.05. Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 7 Kaplan-Meier curves demonstrating progression from normoalbuminuria to microalbuminuria (A; P = 0.04) and from microalbuminuria to overt albuminuria (B; P = 0.02 )in patients on (solid line) intensive versus (dashed line) moderate therapy. Kidney International 2002 61, 1086-1097DOI: (10.1046/j.1523-1755.2002.00213.x) Copyright © 2002 International Society of Nephrology Terms and Conditions